Imugene presented positive clinical Phase Ib data for its HER-Vaxx B-cell vaccine at American Association for Cancer Research (AACR) conference earlier this month. Vaccination successfully broke immune tolerance and stimulated production of HER2-specific antibodies in a dose-dependent fashion; the antibodies inhibited a key component of HER2 signalling. Imugene has initiated a randomised Phase II study of HER-Vaxx in gastric cancer with interim results expected in 2020. It is on track to init
15 Apr 2019
Imugene - HER-Vaxx Phase II underway
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Imugene - HER-Vaxx Phase II underway
Imugene Ltd (IMU:ASX) | 0 0 -4.6% | Mkt Cap: 60.0m
- Published:
15 Apr 2019 -
Author:
Dr Dennis Hulme -
Pages:
11
Imugene presented positive clinical Phase Ib data for its HER-Vaxx B-cell vaccine at American Association for Cancer Research (AACR) conference earlier this month. Vaccination successfully broke immune tolerance and stimulated production of HER2-specific antibodies in a dose-dependent fashion; the antibodies inhibited a key component of HER2 signalling. Imugene has initiated a randomised Phase II study of HER-Vaxx in gastric cancer with interim results expected in 2020. It is on track to init